Clinical and Patient-Reported Outcomes (PROs) in C-POST: A Phase 3 Trial of Adjuvant Cemiplimab Versus Placebo for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s688, 2025. DOI: 10.25251/jy4cvn36. Disponível em: https://skin.dermsquared.com/skin/article/view/3775. Acesso em: 2 may. 2026.